Carsten Brunn, Selecta Biosciences CEO
March 10, 2022 02:10 PM EST
R&D
FDA+

FDA lifts a clin­i­cal hold on Se­lec­ta gene ther­a­py af­ter an­oth­er de­lay ham­pers R&D plans

John Carroll

Editor & Founder

Three months af­ter Se­lec­ta Bio­Sciences got word that the FDA had slapped a clin­i­cal hold on its Phase I/II study of methyl­malonic acidemia drug SEL …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Can­del's vi­ral ther­a­py shows promis­ing sur­vival in small pan­cre­at­ic can­cer study

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times